The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions. Interested in learning more?

In this webinar: 

Attendees will learn important factors in pCODR processes. Presented by Ryan Clarke LL.B., Founder and President of Advocacy Solutions, this webinar will provide the following:

• An overview of drug approval and reimbursement processes
• A closer look at the pCODR process
• A closer look at the pCPA process
• Patterns between pCODR recommendations and pCPA outcomes
• Methodology, findings, and conclusions of CCSN research into pCODR recommendations from 2019
• What can you do if pCODR says “no”
• What should you do if pCODR says “yes” (given COVID-19)

Registration for the webinar: When the pCODR Says "No", Then What? is now open. Join CCSN and Ryan Clarke LL.B. for this educational session aimed at helping cancer patients and survivors become informed on cancer drug assessments and pCODR processes.

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
 
Can't attend?

Be sure to register in order to have a copy of the presentation's slides and Youtube video sent to you after the webinar.